Neoplasm incidence in simultaneous pancreas and kidney transplantation: A single-center analysis

Transplantation Proceedings

Volumn 43, Issue 9, 2011, Pages 3288-3291

  Girman, P ^a   Lipar, K ^a   Kocik, M ^a   Kriz, J ^a   Marada, T ^a   Saudek, F ^a  

^a INSTITUTE FOR CLINICAL AND EXPERIMENTAL MEDICINE   (Czech Republic)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CYCLOSPORIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RAPAMYCIN; T LYMPHOCYTE ANTIBODY; TACROLIMUS;

ACUTE GRAFT REJECTION; ADULT; BASAL CELL CARCINOMA; BLADDER CARCINOMA; CANCER DIAGNOSIS; CANCER INCIDENCE; CANCER PATIENT; CANCER RISK; CANCER SURVIVAL; CONFERENCE PAPER; DIABETIC PATIENT; FEMALE; FOLLOW UP; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY CARCINOMA; KIDNEY PANCREAS TRANSPLANTATION; LUNG ADENOCARCINOMA; LYMPHOPROLIFERATIVE DISEASE; MAJOR CLINICAL STUDY; MALE; MERKEL CELL TUMOR; OVERALL SURVIVAL; PREVALENCE; PRIORITY JOURNAL; REGISTER; RETROSPECTIVE STUDY; SKIN TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH ADENOCARCINOMA; SURVIVAL RATE; THYROID CARCINOMA;

ADULT; BODY MASS INDEX; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; LYMPHOPROLIFERATIVE DISORDERS; MALE; MIDDLE AGED; NEOPLASMS; PANCREAS TRANSPLANTATION; PANCREATIC DISEASES; POSTOPERATIVE COMPLICATIONS; RENAL INSUFFICIENCY; RETROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 81455143615     PISSN: 00411345     EISSN: 18732623     Source Type: Journal    
DOI: 10.1016/j.transproceed.2011.09.011     Document Type: Conference Paper

References (19)

1. F. Tremblay, M. Fernandes, and F. Habbab Malignancy after renal transplantation: incidence and role of type of immunosuppression Ann Surg Oncol 9 2002 785
2. B.L. Kasiske, C.B. Cangro, and S. Hariharan The evaluation of renal transplantation candidates: clinical practice guidelines Am J Transplant 1 suppl 2 2001 3
3. A.G. Sheil, A.P. Disney, T.H. Mathew, and N. Amiss De novo malignancy emerges as a major cause of morbidity and late failure in renal transplantation Transplant Proc 25 1 pt 2 1993 1383
4. G.P. Dunn, A.T. Bruce, and H. Ikeda Cancer immunoediting: from immunosurveillance to tumor escape Nat Immunol 3 2002 991
5. M. Hojo, T. Morimoto, and M. Maluccio Cyclosporine induces cancer progression by a cell- autonomous mechanism Nature 397 6719 1999 530
6. M. Guba, P. von Breitenbuch, and M. Steinbauer Rapamycin inhibits primary and metastatic tumor growth by antiangiogenesis: involvement of vascular endothelial growth factor Nat Med 8 2002 128
7. P. Vigneri, F. Frasca, and L. Sciacca Diabetes and cancer Endocr Relat Cancer 16 2009 1103
8. R.W. Gruessner, D.E. Sutherland, and A.C. Gruessner Mortality assessment for pancreas transplants Am J Transplant 4 2004 2018
9. P. Israel Neoplastic complications of organ transplantation L.C. Ginns, A.B. Cosimi, P.J. Morris, Transplantation 1999 Blackwel Science Cambridge 770
10. L. Dusek Epidemiology of malignant tumors in Czech Republic 2005 http://www.svod.cz
11. National Institute of Public Health http://www.szu.cz
12. N. Issa, H. Amer, and P.G. Dean Posttransplant lymphoproliferative disorder following pancreas transplantation Am J Transplant 9 2009 1894
13. S. Paraskevas, J.E. Coad, and A. Gruessner Posttransplant lymphoproliferative disorder in pancreas transplantation: a single-center experience Transplantation 80 2005 613
14. G. Opelz, V. Daniel, C. Naujokat, and B. Dohler Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma Transplantation 88 2009 962
15. J. Dantal, and J.P. Soulillou Immunosuppressive drugs and the risk of cancer after organ transplantation N Engl J Med 352 2005 1371
16. H.M. Kauffman, W.S. Cherikh, and Y. Cheng Maintenance immunosuppression with target-of-rapamycin inhibitors is associated with a reduced incidence of de novo malignancies Transplantation 80 2005 883
17. R. Salgo, J. Gossmann, and H. Schofer Switch to a sirolimus-based immunosuppression in long-term renal transplant recipients: reduced rate of (pre-)malignancies and nonmelanoma skin cancer in a prospective, randomized, assessor-blinded, controlled clinical trial Am J Transplant 10 2010 1385
18. F.P. Schena, M.D. Pascoe, and J. Alberu Conversion from calcineurin inhibitors to sirolimus maintenance therapy in renal allograft recipients: 24-month efficacy and safety results from the CONVERT trial Transplantation 87 2009 233
19. J.M. Campistol, J. Albanell, and W. Arns Use of proliferation signal inhibitors in the management of post-transplant malignanciesclinical guidance Nephrol Dial Transplant 22 suppl 1 2007 i36